Thermo Fisher Scientific
Biopharmaceuticals represent over $150 Billion in revenue globally each year and continues to grow. Alongside this there is the requirement for the comprehensive characterization of biopharmaceuticals during all stages of drug development and manufacture to ensure safety and efficacy. Liquid chromatography with mass spectrometry (LC-MS) allows the characterization of intact and digested biopharmaceuticals, typically antibodies, to determine glycosylation patterns, charge variants, antibody-drug conjugate ratio determination and more.
Register to view our on-demand seminar to learn about the latest chromatographic workflows for biotherapeutic proteins, including new chemistries and UHPLC enhancements to provide faster, more reproducible and information-rich workflows.
* Required field